BEAM THERAPEUTICS INC stock forecast: up to 38.85 USD BEAM stock price prognosis

STOCK

Forecast for Thu 23 May 2024 price 38.95

BEAM THERAPEUTICS INC stock price forecast for further price development up to 16.95% (time horizon: 1 day) and price target of 38.85 USD. Short-term (time horizon: 2 weeks) BEAM THERAPEUTICS INC share price prediction for 2024-05-23 with daily closed price projections

Key Facts

Symbol BEAM 

ISIN US07373V1052 

CUSIP 07373V105


Currency USD


Category Biological Products (No Diagnostic Substances)

Forecast price change %

Relative Strength Index (RSI)

Finance numbers

Revenue 24,000.0


Earnings per share -6.51


On our site we made daily predictions for finance products based on statistical analysis. You can export / download forecasted data as CSV file, no login required. The information can be used for day trading.

Summerized Form 10-K with GPT-2

Our vision is to provide life-long cures to patients suffering from serious diseases. In some cases, a new product candidate may only require changing the guide RNA. CRISPR proteins incorporate a programmable component called a guide RNA. By changing the deaminase, we can control which base is edited (e.g., C or A). We believe base editors may be an ideal tool for repairing point mutations. & &# Levels of editing were sustained after long-term hematopoietic engraftment. We have developed several proprietary LNP formulations. These protocols included several shifts working over a seven-day-week protocol. We refer to this license agreement as the Editas License Agreement. In addition, on May 30, 2018, the Right to Try Act was signed into law. The CCPA contains significant penalties for companies that violate its requirements. This also applies to biosimilars. Thus, obtaining and maintaining reimbursement status is time-consuming and costly. Other reform efforts affect pricing or payment for drug products.& & Information on our website is not incorporated by reference herein. As of December 31, 2020, we had an accumulated deficit of $397.6 million. The net losses we incur may fluctuate significantly from quarter to quarter. We were founded and commenced operations in January 2017. Our current technology cannot edit within the mitochondria. We are very early in our development efforts. Currently, all of our product candidates are in preclinical development or in discovery. In certain of our programs, we plan to use LNPs to deliver our base editors. No gene editing therapeutic product has been approved in the United States or in Europe. A failure of one or more clinical trials can occur at any stage of testing. We cannot predict the success of any collaboration that we enter into. The scope of patent protection outside of the United States is also uncertain. The patent was revoked due to loss of priority. Violation of the FCPA can result in significant civil and criminal penalties. We do not expect to pay any dividends for the foreseeable future. In addition, our remediation efforts may not be 91 & successful.

Summerized Form 10-K with GPT-2 https://www.sec.gov/Archives/edgar/data/1745999/000156459021013190/0001564590-21-013190.txt
Candlestick patterns

Candlestick patterns can be used as additional information for price prediction. Following list show which pattern applies on latest price information.

  • Meta analyst score 34.72/100
    • Good financial position.
    • Historical view, profit is growing.
    • Company revenue is not growing faster compared with the industry.

Institutional ownership list is based on filling form information

Holding name Date Amount
A - BARCLAYS PLC 2023-06-30 144532
China Universal Asset Management Co., Ltd. 2023-06-30 1235
VOYA INVESTMENT MANAGEMENT LLC 2022-09-30 87744
MetLife Investment Management, LLC 2022-12-31 33390
MetLife Investment Management, LLC 2022-09-30 34379

Fund ownership list is based on filling form information

Fund name Date Amount Profile
Pacer Funds Trust 2023-07-31 1938 Long
Strategic Trust 2023-11-30 12306 Long
iShares Trust 2023-11-30 28461 Long
SCHWAB STRATEGIC TRUST 2023-11-30 308702 Long
SCHWAB STRATEGIC TRUST 2023-11-30 34575 Long

Insider trading for BEAM THERAPEUTICS INC

CIK Name Date Action T-Test 1day T-Test 7day T-Test 14day T-Test 30day
1786322 Ciaramella Giuseppe 2023-07-21 SALE Accept Accept Accept Accept
1963879 Simon Amy 2023-10-30 SALE Accept Accept Accept Accept
1963878 Bellon Christine 2024-01-03 SALE Accept Accept Accept Accept
1786484 Burrell Terry-ann 2023-04-03 SALE Accept Accept Accept Reject
1786304 Evans John M. 2024-01-31 SALE Accept Accept Accept Accept


Bollinger Bollinger Bands for BEAM THERAPEUTICS INC can provide the information where the market is moving based on price information.


BEAM THERAPEUTICS INC Short Volume Ratio is shown in the diagram. Short volume sales can be seen as an investor sentiment.



Converting prices to returns BEAM THERAPEUTICS INC.


On-Balance Volume information for BEAM THERAPEUTICS INC. On-Balance Volume information can be an indicator for bullish or bearish outcome.



Accumulation / Distribution (A/D) indicator information for BEAM THERAPEUTICS INC. The indicator identify divergences between price and volume flow.


Aroon Oscillator information for BEAM THERAPEUTICS INC. The trend-following indicator can show the strengh of a current trend and likelihood that trend can continue.


Average Directional Index (ADX) information for BEAM THERAPEUTICS INC. The index can be used to identify the strengh of a trend.


Moving Average Convergence Divergence (MACD) for BEAM THERAPEUTICS INC. The indicator helps to predict trend direction and the momentum of the trend.


Stochastic Oscillator as momentum indicator for BEAM THERAPEUTICS INC. The indicator is useful for identifying overbought and oversold levels.


Relative Strength Index (RSI) for BEAM THERAPEUTICS INC. RSI is a momentum oscillator that measures the speed and change of price development. The momentum indicator was created by analyst Welles Wilder. The result compares recent gains and losses over restricted time period. Primary usage of the indicator is to identify overbought or oversold signals. When RSI indicator reaches a value of 70 it could mean that speculators should consider selling, suggests Wilder and Chong. Or vice versa when selling excess at which the RSI Indicators show a value of 30 [ Relative Strength Index for Developing Effective Trading Strategies in Constructing Optimal Portfolio ].


Heikin Ashi trading signals are generated based on the Heikin Ashi candles, which are a type of candlestick that smooths out the price action and can help to identify trends. Heikin Ashi signals can be used to identify both long and short trading opportunities.


The awesome oscillator is a momentum indicator that measures the speed and strength of price movements. It is calculated by subtracting a 34-period simple moving average (SMA) from a 5-period SMA.


The Parabolic SAR indicator is a trend-following indicator that uses a series of dots to indicate when a trend is likely to reverse. The Parabolic SAR is a lagging indicator, meaning that it does not predict reversals, but rather confirms them after they have already occurred.


Moving Average Crossover


52W High 52W Low Market Cap

Similar shares


BEAM THERAPEUTICS INC on Nasdaq

BEAM THERAPEUTICS INC on finviz

Figure below show the stock predictions.
Date Closing price Prediction was updated
2024-05-22 38.85 2024-03-28 07:56
2024-05-23 38.95 2024-03-28 07:56
2024-05-20 38.64 2024-03-28 07:56
2024-05-21 38.75 2024-03-28 07:56
2024-04-30 37.09 2024-03-28 07:56
2024-05-02 37.30 2024-03-28 07:56
2024-04-03 34.73 2024-03-28 07:56
2024-04-08 34.93 2024-03-28 07:56
2024-04-09 35.23 2024-03-28 07:56
2024-04-29 36.97 2024-03-28 07:56
2024-05-13 38.12 2024-03-28 07:56
2024-05-14 38.21 2024-03-28 07:56
2024-03-29 34.30 2024-03-28 07:56
2024-05-15 38.31 2024-03-28 07:56
2024-05-16 38.41 2024-03-28 07:56
2024-04-10 35.30 2024-03-28 07:56
2024-04-11 35.60 2024-03-28 07:56
2024-04-24 36.59 2024-03-28 07:56
2024-04-12 35.50 2024-03-28 07:56
2024-04-04 34.71 2024-03-28 07:56
2024-05-06 37.48 2024-03-28 07:56
2024-04-19 36.30 2024-03-28 07:56
2024-05-09 37.89 2024-03-28 07:56
2024-05-17 38.52 2024-03-28 07:56
2024-04-01 34.45 2024-03-28 07:56
2024-04-05 34.89 2024-03-28 07:56
2024-04-18 36.04 2024-03-28 07:56
2024-04-22 36.42 2024-03-28 07:56
2024-04-23 36.54 2024-03-28 07:56
2024-05-01 37.22 2024-03-28 07:56
2024-05-03 37.40 2024-03-28 07:56
2024-05-08 37.74 2024-03-28 07:56
2024-04-02 34.51 2024-03-28 07:56
2024-04-15 35.62 2024-03-28 07:56
2024-04-16 35.61 2024-03-28 07:56
2024-04-17 35.83 2024-03-28 07:56
2024-04-25 36.70 2024-03-28 07:56
2024-04-26 36.82 2024-03-28 07:56
2024-05-07 37.61 2024-03-28 07:56
2024-05-10 38.01 2024-03-28 07:56

The forecast (dashed curve) of the share price performance is based on historical data. Our forecast model is based on mathematical, statistical methods. The website offers price forecasts and analysis tools for equities and other securities, which are exclusively based on the prices of these securities in the past. Information about these prices is provided to us by third parties. Although we believe, If we believe that our sources are reliable, we cannot guarantee the accuracy, completeness, timeliness and correct sequencing of this information. We do not investigate the issuers of the securities to which our forecasts relate, nor do we consider any financial data or other data of such issuers with the exception of the past prices of the securities. Therefore, our forecasts do not constitute an analysis of other commercial or financial factors or circumstances, that may be relevant for future security price flows. Investments require additional considerations. Our forecasts cannot reflect the specific situation. Experience and risk profile of an individual investor or the tax implications an investment may have for the investor. Although we believe that our mathematical models are a tool to try to explore the possibility for future price development with the help of past performance, such developments are subject to a multitude of different influences. and therefore not really predictable. We cannot guarantee the success of any investment you make based on the information published here. This website is for information purposes only. All information and data on this website cannot be guaranteed to be accurate, accuracy, completeness and appropriateness - neither explicit nor implicit.